Demo
Close Language Tab
Locate us
Languages
N
Neuland Laboratories Ltd Pharmaceuticals
₹ 16,158.00 +752.00 (4.88%)
  • NSE
  • BSE

Overview

  • BSE Code 524558
  • NSE Symbol NEULANDLAB
  • ISIN Demat INE794A01010
  • Book Value (₹) 1,182.30
  • Face Value (₹) 10.00
  • Market Cap (₹ Cr.) 20,582.16
  • P/E (TTM) 157.77
  • EPS (TTM) 101.68
  • Div Yield (%) 0.08

Performance

Today’s Low 15,398.00
Today’s High 16,205.00

16,158.00
52W Low 10,190.70
52W High 18,100.00

16,158.00
Open 15,500.00
Prev. Close 15,406.00
Volume 14,890.00

Corporate Actions

Neuland Laboratories Limited - Trading Window
Sep 25, 2025

Neuland Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Neuland Laboratories Limited - Board Meeting Intimation
Apr 24, 2025

NEULAND LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 15-May-2025 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2025 and Dividend.

About Neuland Laboratories Ltd

Set up in 1984 as a private limited company to manufacture bulk drugs, Neuland Laboratories (NLL) is promoted by D R Rao. Neuland Drugs & Pharmaceuticals Pvt Ltd, a company set up by the same promoters to manufacture bulk drugs was merged with NLL with effect from Apr.'92. NLL manufactures bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. _x000D_ _x000D_ It came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr._x000D_ _x000D_ NLL's products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate._x000D_ _x000D_ During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form._x000D_ _x000D_ Mirtrazapine, an anti-depressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI._x000D_ _x000D_ The company is closely working with several companies in Europe and North America for supply of active pharmaceutical ingredients and intermediates._x000D_
Founded: 1984
Chairman: D Saharsh Rao
Managing Director: D Saharsh Rao
Address: 11 Th Floor Phoenix IVY Buildi, Plot No 573A-III Road No 82, Hyderabad, Telangana, 500035,
HO Tel: 91-40-30211600

Frequently Asked Questions

What is the price of Neuland Laboratories Ltd share today? +
How to buy stock of Neuland Laboratories Ltd? +
What is the 52 Week High and Low of Neuland Laboratories Ltd? +
What is the PE ratio of Neuland Laboratories Ltd? +
What is the Market Cap of Neuland Laboratories Ltd? +